Abstract
Background: Recent studies have identified the combination of vancomycin with piperacillin-tazobactam (VPT) to be associated with increased nephrotoxicity. Multiple, large cohort studies have found this widely used combination to have a higher risk of nephrotoxicity than other regimens in a variety of populations. Summary: This review summarizes the epidemiology and clinical features of VPT-associated acute kidney injury (AKI). Potential mechanisms involved in the pathogenesis of this phenomenon are also discussed. Key Message: VPT-associated nephrotoxicity is a recently recognized clinical entity. Clinical strategies to minimize the risk of toxicity in this setting include antimicrobial stewardship, monitoring of kidney function, and emerging data supporting the potential role for novel biomarkers in predicting and managing AKI.
References
1.
Elyasi
S
, Khalili
H
, Dashti-Khavidaki
S
, Mohammadpour
A
. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review
. Eur J Clin Pharmacol
. 2012 Sep 1
;68
(9
):1243
–55
. .2.
Burgess
LD
, Drew
RH
. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam
. Pharmacotherapy
. 2014 Jul
;34
(7
):670
–6
. .3.
Luther
MK
, Timbrook
TT
, Caffrey
AR
, Dosa
D
, Lodise
TP
, LaPlante
KL
. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis
. Crit Care Med
. 2018 Jan
;46
(1
):12
–20
. .4.
Liu
TJ
, Lam
JP
. Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis
. Am J Health Syst Pharm
. 2012 Jul 1
;69
(13
):1109
. .5.
Pill
MW
, O’Neill
CV
, Chapman
MM
, Singh
AK
. Suspected acute interstitial nephritis induced by piperacillin-tazobactam
. Pharmacotherapy
. 1997 Jan–Feb
;17
(1
):166
–9
.6.
Hellwig
T
, Hammerquist
R
, Loecker
B
, Shields
J
. Retrospective evaluation of the incidence of vancomycin and/or piperacillin-tazobactam induced acute renal failure
. Crit Care Med
. 2011
;39
(12
):79
.7.
Bagshaw
SM
, George
C
, Bellomo
R
, Committee
ADM
. Early acute kidney injury and sepsis: a multicentre evaluation
. Crit Care
. 2008
;12
(2
):R47
. .8.
Min
E
, Box
K
, Lane
J
, Sanchez
J
, Coimbra
R
, Doucet
J
, et al. Acute kidney injury in patients recieving concomitant vancomycin and piperacillin/tazobactam
. Crit Care Med
. 2011
;39
(12
):200
.9.
Kang
S
, Park
J
, Yu
YM
, Park
MS
, Han
E
, Chang
MJ
. Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit
. PLoS One
. 2019
;14
(6
):e0217908
. .10.
Molina
KC
, Barletta
JF
, Hall
ST
, Yazdani
C
, Huang
V
. The risk of acute kidney injury in critically ill patients receiving concomitant vancomycin with piperacillin-tazobactam or cefepime
. J Intensive Care Med
. 2019
;35
:1434
–8
.11.
Blevins
AM
, Lashinsky
JN
, McCammon
C
, Kollef
M
, Micek
S
, Juang
P
. Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem
. Antimicrob Agents Chemother
. 2019 May
;63
(5
):e02658
. .12.
Rutter
WC
, Cox
JN
, Martin
CA
, Burgess
DR
, Burgess
DS
. Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime
. Antimicrob Agents Chemother
. 2017 Feb
;61
(2
):e02089
. .13.
Robertson
AD
, Li
C
, Hammond
DA
, Dickey
TA
. Incidence of acute kidney injury among patients receiving the combination of vancomycin with piperacillin-tazobactam or meropenem
. Pharmacotherapy
. 2018 Dec
;38
(12
):1184
–93
. .14.
Clemmons
AB
, Bech
CF
, Pantin
J
, Ahmad
I
. Acute kidney injury in hematopoietic cell transplantation patients receiving vancomycin and piperacillin/tazobactam versus vancomycin and cefepime
. Biol Blood Marrow Transplant
. 2018 Apr
;24
(4
):820
–6
. .15.
Jeon
N
, Staley
B
, Klinker
KP
, Hincapie Castillo
J
, Winterstein
AG
. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function
. Int J Antimicrob Agents
. 2017 Jul
;50
(1
):63
–7
. .16.
Gomes
DM
, Smotherman
C
, Birch
A
, Dupree
L
, Della Vecchia
BJ
, Kraemer
DF
, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime
. Pharmacotherapy
. 2014 Jul
;34
(7
):662
–9
. .17.
Navalkele
B
, Pogue
JM
, Karino
S
, Nishan
B
, Salim
M
, Solanki
S
, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime
. Clin Infect Dis
. 2017 Jan 15
;64
(2
):116
–23
. .18.
Buckley
MS
, Hartsock
NC
, Berry
AJ
, Bikin
DS
, Richards
EC
, Yerondopoulos
MJ
, et al. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit
. J Crit Care
. 2018 Dec 1
;48
:32
–8
. .19.
Hammond
DA
, Smith
MN
, Painter
JT
, Meena
NK
, Lusardi
K
. Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study
. Pharmacotherapy
. 2016 May
;36
(5
):463
–71
. .20.
Rutter
WC
, Burgess
DS
. Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin
. Antimicrob Agents Chemother
. 2018
;62
(7
):e00264
–18
. .21.
Peyko
V
, Smalley
S
, Cohen
H
. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin
. J Pharm Pract
. 2017 Apr
;30
(2
):209
–13
. .22.
McQueen
KE
, Clark
DW
. Does combination therapy with vancomycin and piperacillin-tazobactam increase the risk of nephrotoxicity versus vancomycin alone in pediatric patients?
J Pediatr Pharmacol Ther
. 2016 Jul–Aug
;21
(4
):332
–8
. .23.
Cook
KM
, Gillon
J
, Grisso
AG
, Banerjee
R
, Jimenez-Truque
N
, Phillips
EJ
, et al. Incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: a cohort study
. J Pediatric Infect Dis Soc
. 2019 Jul 1
;8
(3
):221
–7
. .24.
Downes
KJ
, Cowden
C
, Laskin
BL
, Huang
YS
, Gong
W
, Bryan
M
, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children
. JAMA Pediatr
. 2017 Dec 4
;171
(12
):e173219
. .25.
Al Nuhait
M
, Abu Esba
LC
, Al Harbi
K
, Al Meshary
M
, Bustami
RT
. Acute kidney injury in pediatric treated with vancomycin and piperacillin-tazobactam in tertiary care hospital
. Int J Pediatr
. 2018 Dec 16
;2018
:e585
–91
. .26.
LeCleir
LK
, Pettit
RS
. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients
. Pediatr Pulmonol
. 2017 Aug
;52
(8
):1000
–5
. .27.
Quach
HT
, Esbenshade
AJ
, Zhao
Z
, Banerjee
R
. Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime
. Pediatr Blood Cancer
. 2019 Jul 1
;66
(7
):e27750
. .28.
Joyce
EL
, Kane-Gill
SL
, Priyanka
P
, Fuhrman
DY
, Kellum
JA
. Piperacillin/tazobactam and antibiotic-associated acute kidney injury in critically ill children
. J Am Soc Nephrol
. 2019 Nov
;30
(11
):2243
–51
. .29.
Schreier
DJ
, Kashani
KB
, Sakhuja
A
, Mara
KC
, Tootooni
MS
, Personett
HA
, et al. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal β-lactams with vancomycin
. Clin Infect Dis
. 2019 Apr 24
;68
(9
):1456
–62
. .30.
Chen
XY
, Xu
RX
, Zhou
X
, Liu
Y
, Hu
CY
, Xie
XF
. Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis
. Int Urol Nephrol
. 2018 Nov
;50
(11
):2019
–26
. .31.
Giuliano
CA
, Patel
CR
, Kale-Pradhan
PB
. Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis
. Pharmacotherapy
. 2016 Dec
;36
(12
):1217
–28
. .32.
Mellen
CK
, Ryba
JE
, Rindone
JP
. Does piperacillin-tazobactam increase the risk of nephrotoxicity when used with vancomycin: a meta-analysis of observational trials
. Curr Drug Saf
. 2017
;12
(1
):62
–6
. .33.
Ciarambino
T
, Giannico
OV
, Campanile
A
, Tirelli
P
, Para
O
, Signoriello
G
, et al. Acute kidney injury and vancomycin/piperacillin/tazobactam in adult patients: a systematic review
. Intern Emerg Med
. 2020 Mar
;15
(2
):327
–31
. .34.
Bellos
I
, Karageorgiou
V
, Pergialiotis
V
, Perrea
DN
. Acute kidney injury following the concurrent administration of antipseudomonal beta-lactams and vancomycin: a network meta-analysis
. Clin Microbiol Infect
. 2020 Mar 25
;26
:696
–705
.35.
Hammond
DA
, Smith
MN
, Li
C
, Hayes
SM
, Lusardi
K
, Bookstaver
PB
. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam
. Clin Infect Dis
. 2017 Mar 1
;64
(5
):666
–74
. .36.
Avedissian
SN
, Pais
GM
, Liu
J
, Rhodes
NJ
, Scheetz
MH
. Piperacillin-tazobactam added to vancomycin increases risk for aki: fact or fiction?
Clin Infect Dis
. 2019 Dec 13
;71
:426
–32
.37.
Moenster
RP
, Linneman
TW
, Finnegan
PM
, Hand
S
, Thomas
Z
, McDonald
JR
. Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime
. Clin Microbiol Infect
. 2014 Jun
;20
(6
):O384
–9
.38.
Karino
S
, Kaye
KS
, Navalkele
B
, Nishan
B
, Salim
M
, Solanki
S
, et al. Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin-tazobactam: opportunities for antimicrobial stewardship
. Antimicrob Agents Chemother
. 2016
;60
(6
):3743
–50
. .39.
Anderson
CW
, Cazares
KS
, Lustik
MB
, Patel
SM
, Denunzio
TM
. Vancomycin vs. vancomycin/piperacillin-tazobactam-associated acute kidney injury in noncritically ill patients at a tertiary care military treatment facility
. Mil Med
. 2017 Sep
;182
(9
):e1773
–e1778
. .40.
Neely
MN
, Youn
G
, Jones
B
, Jelliffe
RW
, Drusano
GL
, Rodvold
KA
, et al. Are vancomycin trough concentrations adequate for optimal dosing?
Antimicrob Agents Chemother
. 2014
;58
(1
):309
–16
. .41.
Aljefri
DM
, Avedissian
SN
, Rhodes
NJ
, Postelnick
MJ
, Nguyen
K
, Scheetz
MH
. Vancomycin area under the curve and acute kidney injury: a meta-analysis
. Clin Infect Dis
. 2019
;69
(11
):1881
–7
. .42.
Mergenhagen
KA
, Borton
AR
. Vancomycin nephrotoxicity: a review
. J Pharm Pract
. 2014 Dec
;27
(6
):545
–53
. .43.
Zhu
LL
, Zhou
Q
. Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years
. Infect Drug Resist
. 2018
;11
:1105
–17
. .44.
Dulhunty
JM
, Roberts
JA
, Davis
JS
, Webb
SA
, Bellomo
R
, Gomersall
C
, et al. A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis
. Am J Respir Crit Care Med
. 2015 Dec 1
;192
(11
):1298
–305
. .45.
Cotner
SE
, Rutter
WC
, Burgess
DR
, Wallace
KL
, Martin
CA
, Burgess
DS
. Influence of β-lactam infusion strategy on acute kidney injury
. Antimicrob Agents Chemother
. 2017
;61
(10
):e00871
–17
. .46.
Mousavi
M
, Zapolskaya
T
, Scipione
MR
, Louie
E
, Papadopoulos
J
, Dubrovskaya
Y
. Comparison of rates of nephrotoxicity associated with vancomycin in combination with piperacillin-tazobactam administered as an extended versus standard infusion
. Pharmacotherapy
. 2017 Mar
;37
(3
):379
–85
. .47.
Bamgbola
O
. Review of vancomycin-induced renal toxicity: an update
. Ther Adv Endocrinol Metab
. 2016 Jun
;7
(3
):136
–47
. .48.
Horey
A
, Mergenhagen
KA
, Mattappallil
A
. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran’s population: a retrospective analysis
. Ann Pharmacother
. 2012 Nov
;46
(11
):1477
–83
.49.
Rutter
WC
, Hall
RG
, Burgess
DS
. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin
. Am J Health Syst Pharm
. 2019 Aug 1
;76
(16
):1211
–7
. .50.
Minejima
E
, Choi
J
, Beringer
P
, Lou
M
, Tse
E
, Wong-Beringer
A
. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients
. Antimicrob Agents Chemother
. 2011
;55
(7
):3278
. .51.
Balci
C
, Uzun
O
, Arici
M
, Hayran
SA
, Yuce
D
, Unal
S
. Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
Int J Antimicrob Agents
. 2018 Aug
;52
(2
):180
–4
.52.
Davies
SW
, Efird
JT
, Guidry
CA
, Dietch
ZC
, Willis
RN
, Shah
PM
, et al. Top guns: the “Maverick” and “Goose” of empiric therapy
. Surg Infect
. 2016
;17
(1
):38
–47
. .53.
Carreno
J
, Smiraglia
T
, Hunter
C
, Tobin
E
, Lomaestro
B
. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy
. Int J Antimicrob Agents
. 2018 Nov
;52
(5
):643
–50
. .54.
Rutter
WC
, Burgess
DS
. Acute kidney injury in patients treated with IV beta-lactam/beta-lactamase inhibitor combinations
. Pharmacotherapy
. 2017
;37
(5
):593
–8
. .55.
Mullins
BP
, Kramer
CJ
, Bartel
BJ
, Catlin
JS
, Gilder
RE
. Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin/tazobactam: a prospective, multicenter study
. Ann Pharmacother
. 2018
;52
(7
):639
–44
. .56.
Kane-Gill
SL
, Ostermann
M
, Shi
J
, Joyce
EL
, Kellum
JA
. Evaluating renal stress using pharmacokinetic urinary biomarker data in critically ill patients receiving vancomycin and/or piperacillin-tazobactam: a secondary analysis of the multicenter sapphire study
. Drug Saf
. 2019 Oct
;42
(10
):1149
–55
. .57.
Pais
GM
, Liu
J
, Avedissian
SN
, Hiner
D
, Xanthos
T
, Chalkias
A
, et al. Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model
. J Antimicrob Chemother
. 2020 May 1
;75
(5
):1228
–36
. .58.
Pratt
JA
, Stricherz
MK
, Verghese
PS
, Burke
MJ
. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population
. Pediatr Blood Cancer
. 2014 Feb
;61
(2
):366
–8
. .59.
Sawada
A
, Kawanishi
K
, Morikawa
S
, Nakano
T
, Kodama
M
, Mitobe
M
, et al. Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review
. BMC Nephrol
. 2018
;19
(1
):72
. .60.
Sokol
H
, Vigneau
C
, Maury
E
, Guidet
B
, Offenstadt
G
. Biopsy-proven anuric acute tubular necrosis associated with vancomycin and one dose of aminoside
. Nephrol Dial Transplant
. 2004
;19
(7
):1921
–2
. .61.
German
P
, Liu
HC
, Szwarcberg
J
, Hepner
M
, Andrews
J
, Kearney
BP
, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function
. J Acquir Immune Defic Syndr
. 2012 Sep 1
;61
(1
):32
–40
. .62.
Choudhury
D
, Ahmed
Z
. Drug-associated renal dysfunction and injury
. Nat Clin Pract Nephrol
. 2006 Feb
;2
(2
):80
–91
. .63.
Nolin
TD
. Vancomycin and the risk of AKI: now clearer than Mississippi mud
. Clin J Am Soc Nephrol
. 2016
;11
(12
):2101
–3
.64.
Oktem
F
, Arslan
MK
, Ozguner
F
, Candir
O
, Yilmaz
HR
, Ciris
M
, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: Protection by erdosteine
. Toxicology
. 2005 Nov 15
;215
(3
):227
–33
. .65.
Nishino
Y
, Takemura
S
, Minamiyama
Y
, Hirohashi
K
, Ogino
T
, Inoue
M
, et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats
. Free Radic Res
. 2003 Apr
;37
(4
):373
–9
. .66.
Arimura
Y
, Yano
T
, Hirano
M
, Sakamoto
Y
, Egashira
N
, Oishi
R
. Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis
. Free Radic Biol Med
. 2012 May 1
;52
(9
):1865
–73
. .67.
Dalaklioglu
S
, Tekcan
M
, Gungor
NE
, Celik-Ozenci
C
, Aksoy
NH
, Baykal
A
, et al. Role of the poly(ADP-ribose)polymerase activity in vancomycin-induced renal injury
. Toxicol Lett
. 2010 Feb 1
;192
(2
):91
–6
. .68.
Waring
WS
, Moonie
A
. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury
. Clin Toxicol
. 2011 Oct
;49
(8
):720
–8
. .69.
Luque
Y
, Louis
K
, Jouanneau
C
, Placier
S
, Esteve
E
, Bazin
D
, et al. Vancomycin-associated cast nephropathy
. J Am Soc Nephrol
. 2017 Jun
;28
(6
):1723
–8
. .70.
Soto
J
, Bosch
JM
, Alsar Ortiz
MJ
, Moreno
MJ
, Gonzalez
JD
, Diaz
JM
. Piperacillin-induced acute interstitial nephritis
. Nephron
. 1993
;65
(1
):154
–5
. .71.
Moledina
DG
, Perazella
MA
. Drug-induced acute interstitial nephritis
. Clin J Am Soc Nephrol
. 2017 Dec 7
;12
(12
):2046
–9
. .72.
Manian
FA
. Should we revisit the nephrotoxic potential of piperacillin-tazobactam as well?
Clin Infect Dis
. 2017 Jul 1
;65
(1
):178
. .73.
Shemesh
O
, Golbetz
H
, Kriss
JP
, Myers
BD
. Limitations of creatinine as a filtration marker in glomerulopathic patients
. Kidney Int
. 1985 Nov
;28
(5
):830
–8
. .74.
Vallon
V
, Eraly
SA
, Rao
SR
, Gerasimova
M
, Rose
M
, Nagle
M
, et al. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice
. Am J Physiol Renal Physiol
. 2012 May 15
;302
(10
):F1293
–9
. .75.
Sekine
T
, Miyazaki
H
, Endou
H
. Molecular physiology of renal organic anion transporters
. Am J Physiol Renal Physiol
. 2006 Feb
;290
(2
):F251
–61
. .76.
Lepist
EI
, Zhang
X
, Hao
J
, Huang
J
, Kosaka
A
, Birkus
G
, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat
. Kidney Int
. 2014 Aug
;86
(2
):350
–7
. .77.
Tanihara
Y
, Masuda
S
, Sato
T
, Katsura
T
, Ogawa
O
, Inui
K
. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters
. Biochem Pharmacol
. 2007 Jul 15
;74
(2
):359
–71
. .78.
Ciarimboli
G
, Lancaster
CS
, Schlatter
E
, Franke
RM
, Sprowl
JA
, Pavenstädt
H
, et al. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients
. Clin Cancer Res
. 2012 Feb 15
;18
(4
):1101
–8
. .79.
Kaler
G
, Truong
DM
, Khandelwal
A
, Nagle
M
, Eraly
SA
, Swaan
PW
, et al. Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members
. J Biol Chem
. 2007 Aug 17
;282
(33
):23841
–53
. .80.
Andreev
E
, Koopman
M
, Arisz
L
. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?
J Intern Med
. 1999 Sep
;246
(3
):247
–52
. .81.
Wen
S
, Wang
C
, Duan
Y
, Huo
X
, Meng
Q
, Liu
Z
, et al. OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam
. Int J Pharm
. 2018 Feb 15
;537
(1–2
):172
–82
. .82.
Wen
S
, Wang
C
, Huo
X
, Meng
Q
, Liu
Z
, Yang
S
, et al. JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats
. Toxicol Lett
. 2018 Oct 01
;295
:195
–204
. .83.
Jensen
JU
, Hein
L
, Lundgren
B
, Bestle
MH
, Mohr
T
, Andersen
MH
, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial
. BMJ Open
. 2012
;2
(2
):e000635
. .84.
Pais
GM
, Avedissian
SN
, O’Donnell
JN
, Rhodes
NJ
, Lodise
TP
, Prozialeck
WC
, et al. Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury
. Antimicrob Agents Chemother
. 2019
;63
(7
):e00079
–19
. .85.
Barlam
TF
, Cosgrove
SE
, Abbo
LM
, MacDougall
C
, Schuetz
AN
, Septimus
EJ
, et al. Implementing an antibiotic stewardship program: Guidelines by the infectious diseases society of america and the society for healthcare epidemiology of america
. Clin Infect Dis
. 2016 May 15
;62
(10
):e51
–77
.86.
Liu
C
, Bayer
A
, Cosgrove
SE
, Daum
RS
, Fridkin
SK
, Gorwitz
RJ
, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children
. Clin Infect Dis
. 2011
;52
(3
):e18
–55
. .87.
Freifeld
AG
, Bow
EJ
, Sepkowitz
KA
, Boeckh
MJ
, Ito
JI
, Mullen
CA
, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America
. Clin Infect Dis
. 2011
;52
(4
):427
–31
. .88.
Baddour
LM
, Wilson
WR
, Bayer
AS
, Fowler
VG
Jr, Tleyjeh
IM
, Rybak
MJ
, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the american heart association
. Circulation
. 2015 Oct 13
;132
(15
):1435
–86
. .89.
Rhodes
A
, Evans
LE
, Alhazzani
W
, Levy
MM
, Antonelli
M
, Ferrer
R
, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock
. Intensive Care Med
. 20162017 Mar
;43
(3
):304
–77
.90.
Tabah
A
, Bassetti
M
, Kollef
MH
, Zahar
JR
, Paiva
JA
, Timsit
JF
, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European society of intensive care medicine (ESICM) and European society of clinical microbiology and infectious diseases (ESCMID) critically ill patients study group (ESGCIP)
. Intensive Care Med
. 2020 Feb
;46
(2
):245
–65
. .91.
De Waele
JJ
, Schouten
J
, Beovic
B
, Tabah
A
, Leone
M
. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions-a viewpoint of experts
. Intensive Care Med
. 2020 Feb
;46
(2
):236
–44
. .92.
Dangerfield
B
, Chung
A
, Webb
B
, Seville
MT
. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia
. Antimicrob Agents Chemother
. 2014
;58
(2
):859
–64
. .93.
Schaffzin
JK
, Dodd
CN
, Nguyen
H
, Schondelmeyer
A
, Campanella
S
, Goldstein
SL
. Administrative data misclassifies and fails to identify nephrotoxin-associated acute kidney injury in hospitalized children
. Hosp Pediatr
. 2014 May
;4
(3
):159
–66
. .94.
Norton
K
, Ingram
PR
, Heath
CH
, Manning
L
. Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital
. J Antimicrob Chemother
. 2014 Mar
;69
(3
):805
–8
. .95.
Goldstein
SL
, Dahale
D
, Kirkendall
ES
, Mottes
T
, Kaplan
H
, Muething
S
, et al. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children
. Kidney Int
. 2020 Mar
;97
(3
):580
–8
. .96.
Redahan
L
, Murray
PT
. Novel biomarkers of drug-induced kidney injury
. Clin Pharmacol Ther
. 2018 Mar
;103
(3
):396
–8
. .97.
Rybak
MJ
, Le
J
, Lodise
TP
, Levine
DP
, Bradley
JS
, Liu
C
, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists
. Am J Health Syst Pharm
. 2020
;77
(11
):835
–64
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
